Taking stock: A multistakeholder perspective on improving the delivery of care and the development of treatments for Alzheimer's disease-Reference-Cited by-同舟云学术

Taking stock: A multistakeholder perspective on improving the delivery of care and the development of treatments for Alzheimer's disease

Published:2014-04-21 Issue:4 Volume:11 Page:455-461
ISSN:1552-5260
Container-title:Alzheimer's & Dementia
language:en
Short-container-title:Alzheimer's & Dementia

Author:

Bradley Patrick¹,Akehurst Ron²,Ballard Clive³,Banerjee Sube⁴,Blennow Kaj⁵,Bremner Jennifer⁶,Broich Karl⁷,Cummings Jeffrey⁸,Dening Karen⁹,Dubois Bruno¹⁰,Klipper Wiebke¹¹¹²,Leibman Chris¹²¹³,Mantua Valentina¹⁴,Molinuevo José Luis¹⁵¹⁶,Morgan Susan¹⁷,Muscolo Luisa A.A.¹⁴,Nicolas François¹⁸¹⁹,Pani Luca¹⁴,Robinson Louise²⁰,Siviero Paolo¹⁴,Dam Julius²¹,VanEmelen Jan²²,Wimo Anders²³,Wortmann Marc²⁴,Goh Lindee¹

Affiliation:

1. Tapestry Networks (US Office) Waltham MA USA

2. School of Health & Related Research (ScHARR) University of Sheffield Sheffield UK

3. Wolfson Centre for Age Related Diseases King's College London London UK

4. Brighton & Sussex Medical School University of Sussex Brighton UK

5. Clinical Neurochemistry Laboratory Department of Psychiatry & Neurochemistry Institute of Neuroscience & Physiology The Sahlgrenska Academy at University of Gothenburg Mölndal Sweden

6. European Health Management Association (EHMA) Brussels Belgium

7. Federal Institute for Drugs & Medical Devices (BfArM) Bonn Germany

8. Lou Ruvo Center for Brain Health Cleveland Clinic Las Vegas NV USA

9. Admiral Nursing Dementia UK London UK

10. Alzheimer Institute (IM2A) Salpêtrière University Hospital, UPMC Paris France

11. Pharmaceuticals Department Federal Joint Committee (G‐BA) Berlin Germany

12. Biogen Idec Cambridge MA USA

13. Janssen Alzheimer Immunotherapy Research & Development LLC

14. Italian Medicines Agency (AIFA) Rome Italy

15. Alzheimer's Disease and Other Cognitive Disorders Unit Barcelona Clinical Hospital Barcelona Spain

16. Early Detection Programme Pasqual Maragall Foundation Barcelona Spain

17. Medicines & Healthcare Products Regulatory Agency (MHRA) London UK

18. Sanofi S.A. Paris France

19. PET Neurology, GE Healthcare

20. Primary Care & Ageing, Institute of Health and Society Newcastle University Newcastle upon Tyne UK

21. Independent Consultant in Reimbursement & Pharmacy Zwolle Netherlands

22. Association Internationale de la Mutualité Brussels Belgium

23. Alzheimer's Disease Research Centre Karolinska Institutet Stockholm Sweden

24. Alzheimer's Disease International (ADI) London UK

Publisher

Wiley

Subject

Psychiatry and Mental health,Cellular and Molecular Neuroscience,Geriatrics and Gerontology,Clinical Neurology,Developmental Neuroscience,Health Policy,Epidemiology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1016/j.jalz.2014.01.007

Reference24 articles.

1. The worldwide economic impact of dementia 2010

2. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group* under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

3. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria

4. Revising the definition of Alzheimer's disease: a new lexicon

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mechanism of Neural Regeneration Induced by Natural Product LY01 in the 5×FAD Mouse Model of Alzheimer’s Disease;Frontiers in Pharmacology;2022-06-22

2. Clinical Trial Endpoints and Their Clinical Meaningfulness in Early Stages of Alzheimer’s Disease;The Journal Of Prevention of Alzheimer's Disease;2022

3. Biomarker Testing: Piercing the Fog of Alzheimer’s and Related Dementia;Biomedicine Hub;2020-11-23

4. Valuing Alzheimer's disease drugs: a health technology assessment perspective on outcomes;International Journal of Technology Assessment in Health Care;2020-08

5. DESIGNING TRIALS OF DISEASE MODIFYING AGENTS FOR EARLY AND PRECLINICAL ALZHEIMER’S DISEASE INTERVENTION: WHAT EVIDENCE IS MEANINGFUL TO PATIENTS, PROVIDERS, AND PAYERS?;The Journal Of Prevention of Alzheimer's Disease;2018